首页 › 伯基特淋巴瘤 › 纽约州 › New York City
New York City NY 伯基特淋巴瘤临床试验
13项针对 伯基特淋巴瘤的研究正在 New York City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
招募中3 期
- Memorial Sloan Kettering Cancer Center, New York
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- 以及另外 1 项
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
招募中3 期
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
招募中2 期
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
招募中3 期
- David H. Koch Center for Cancer Care, New York
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
招募中1/2 期
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
招募中1 期
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
招募中2 期
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
招募中3 期
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- 以及另外 2 项
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
招募中1/2 期
- Research Site, New York
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
招募中2 期
- Memorial Sloan Kettering Cancer Center, New York
Study of SGR-1505 in Mature B-Cell Neoplasms
招募中1 期
- Weill Cornell, New York
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
招募中1/2 期
- Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
其他城市的 伯基特淋巴瘤试验
- Houston, TX21 项研究
- Philadelphia, PA16 项研究
- Milwaukee, WI16 项研究
- Chicago, IL15 项研究
- Cincinnati, OH13 项研究
- Atlanta, GA12 项研究
- Aurora, CO11 项研究
- Seattle, WA11 项研究
- Durham, NC10 项研究
- Boston, MA10 项研究
- Kansas City, MO10 项研究
- Los Angeles, CA10 项研究
New York City的其他研究
- 乳腺癌136 项研究
- 非小细胞肺癌121 项研究
- 癌症（所有类型）109 项研究
- 前列腺癌103 项研究
- 转移性癌症93 项研究
- 结直肠癌78 项研究
- 卵巢癌69 项研究
- 肺癌60 项研究
- 多发性骨髓瘤60 项研究
- 胰腺癌60 项研究
- 子宫内膜癌52 项研究
- 急性髓系白血病51 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。